These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26991555)

  • 21. Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?
    Cebrián-Cuenca AM; Orozco-Beltrán D; Navarro-Pérez J; Franch-Nadal J; Núñez-Villota J; Consuegra-Sánchez L
    Int J Cardiol; 2016 Oct; 220():573-4. PubMed ID: 27390991
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Kundu A; Sardar P; Ghosh S; Patel P; Chatterjee S; Meyer TE
    Int J Cardiol; 2016 Jun; 212():203-5. PubMed ID: 27043061
    [No Abstract]   [Full Text] [Related]  

  • 25. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.
    Men P; He N; Song C; Zhai S
    Diabetes Metab; 2017 Dec; 43(6):493-500. PubMed ID: 28778563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
    Richard KR; Shelburne JS; Kirk JK
    Clin Ther; 2011 Nov; 33(11):1609-29. PubMed ID: 22071236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
    Hardy G
    Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
    [No Abstract]   [Full Text] [Related]  

  • 29. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
    Yang W; Cai X; Han X; Ji L
    Diabetes Metab Res Rev; 2016 May; 32(4):391-404. PubMed ID: 26417956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure　- Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Sato K; Sai S; Sugano A; Obara K; Aonuma K
    Circ J; 2017 Oct; 81(11):1662-1669. PubMed ID: 28592726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
    Shubrook JH; Colucci RA; Schwartz FL
    Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
    Elgendy IY; Mahmoud AN; Barakat AF; Elgendy AY; Saad M; Abuzaid A; Wayangankar SA; Bavry AA
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):143-155. PubMed ID: 27873238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
    Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R
    BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M; Liu Y; Jin J; He Q
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saxagliptin overview: special focus on safety and adverse effects.
    Ali S; Fonseca V
    Expert Opin Drug Saf; 2013 Jan; 12(1):103-9. PubMed ID: 23137182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
    Cook W; Bryzinski B; Slater J; Frederich R; Allen E
    Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.